Technology

Oncternal Therapeutics

$5.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.33 (+6.04%) Today
-$0.05 (-0.94%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ONCT and other stocks, options, and ETFs commission-free!

About ONCT

Oncternal Therapeutics, Inc. Common Stock, also called Oncternal Therapeutics, is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. It focuses on drug development of untapped biological pathways implicated in cancer progression. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA. The listed name for ONCT is Oncternal Therapeutics, Inc. Common Stock.

CEO
James B. Breitmeyer
Employees
14
Headquarters
San Diego, California
Founded
1997
Market Cap
249.76M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.12M
High Today
$5.99
Low Today
$5.36
Open Price
$5.60
Volume
1.99M
52 Week High
$7.19
52 Week Low
$1.49

Collections

ONCT Earnings

-$3.38
-$2.25
-$1.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

XDIV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure